^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    AACR-I 2020
    Title:

    Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups

    Published date:
    04/27/2020
    Excerpt:
    In pts with EGFR/ALK+ tumors and pts with baseline liver mets, OS was comparable in Arms A and C; continued OS benefit in these subgroups was seen in Arm B vs C.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1158/1538-7445.AM2020-CT216
    Trial ID:
    IMpower150